Please Wait
Applying Filters...

Annual Sales of 2 inverted exclamation marka-Deoxy-5-trifluoromethyluridine reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies.

Menu
$ API Ref.Price (USD/KG) : 32,446Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 8Lonsurf

PharmaCompass

01

Brand Name : Lonsurf

Trifluridine

arrow
34th IFSCC
Not Confirmed

Brand Name : Lonsurf

arrow
34th IFSCC
Not Confirmed

Trifluridine

Main Therapeutic Indication : Oncology

Currency : USD

2020 Revenue in Millions : 386

2019 Revenue in Millions : 327

Growth (%) : 18

blank

02

Brand Name : Lonsurf

Trifluridine

arrow
34th IFSCC
Not Confirmed

Brand Name : Lonsurf

arrow
34th IFSCC
Not Confirmed

Trifluridine

Main Therapeutic Indication : Oncology

Currency : USD

2021 Revenue in Millions : 389

2020 Revenue in Millions : 370

Growth (%) : 13

blank

03

Brand Name : Lonsurf

Trifluridine

arrow
34th IFSCC
Not Confirmed

Brand Name : Lonsurf

arrow
34th IFSCC
Not Confirmed

Trifluridine

Main Therapeutic Indication : Oncology

Currency : USD

2022 Revenue in Millions : 435

2021 Revenue in Millions : 389

Growth (%) : 12

blank

04

Brand Name : Lonsurf

Trifluridine

arrow
34th IFSCC
Not Confirmed

Brand Name : Lonsurf

arrow
34th IFSCC
Not Confirmed

Trifluridine

Main Therapeutic Indication : Oncology

Currency : USD

2023 Revenue in Millions : 534

2022 Revenue in Millions : 435

Growth (%) : 39

blank

05

Brand Name : Lonsurf

Trifluridine And Tipiracil

arrow
34th IFSCC
Not Confirmed

06

Brand Name : Lonsurf

Trifluridine and Tipiracil

arrow
34th IFSCC
Not Confirmed

07

Brand Name : Lonsurf

Trifluridine and Tipiracil

arrow
34th IFSCC
Not Confirmed

08

Brand Name : Lonsurf

Trifluridine

arrow
34th IFSCC
Not Confirmed

Brand Name : Lonsurf

arrow
34th IFSCC
Not Confirmed

Trifluridine

Main Therapeutic Indication : Oncology

Currency : USD

2019 Revenue in Millions : 321

2018 Revenue in Millions : 283

Growth (%) : 13

blank